The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Exact Sciences (EXAS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

Exact Sciences Stock: Beats Its Own Guide Total second-quarter revenue climbed 12% to $699.3 million, above expectations for $690 million and Exact's own guidance for $677 million to $697 million ...

Key Points Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers.

Exact Sciences is beginning to stem losses and is continuing to grow revenue at a reasonable clip. Despite this, GAAP profitability is still far into the future, and the 2023 guidance is mediocre.

Exact Sciences Earnings: Robust Growth Due to Screening, New Products Launching on Schedule Jay Lee May 5, 2025 ...

Last year, Exact Sciences burned through $223.6 million in cash just from its day-to-day operations. And that was a significant increase from the $102.2 million it used up in the previous year.

First, more providers than ever are now prescribing Cologuard. Exact Sciences recently reported that around 147,000 providers have adopted the DNA cancer test, which reflects a CAGR of 76% since 2014.

Exact Sciences Corporation EXAS is well poised for growth in the coming quarters, led by strong Cologuard growth. The raised 2023 guidance is a major upside. However, mounting expenses and stiff ...

June 20 (Reuters) - Exact Sciences (EXAS.O), opens new tab said on Tuesday its next-generation screening test for colon cancer showed 30% lower false positive rate for detecting the disease in a ...